Ventilation and Perfusion in Asthmatics
Study Details
Design, interventions, and primary outcomes
About This Study
Assess regional changes to perfusion and ventilation from inhaled corticosteroid (ICS) and Fast-acting beta-antagonist (FABA) among adult asthmatics using radiographically derived estimates of regional ventilation (V-distribution), ventilation defect percentage (VDP), and ventilation heterogeneity (VH).
Design
Interventions / Regimen
- Drug: Albuterol Sulfate — Visit 1: Albuterol Sulfate (90mcg) two puffs will be administered via metered-dose inhaler (MDI) with spacer during the baseline study visit to obtain baseline imaging values.
- Drug: Albuterol-Budesonide — Visit 2: AIRSUPRA (Albuterol/Budesonide) (90mcg/80mcg) two puffs will be administered via MDI with spacer during this study visit. This intervention is used to evaluate its effect on ventilation defect percentage (VDP), ventilation heterogeneity (VH), and perfusion metrics derived from XV LVAS imaging
Primary Outcomes
- Change in Regional Ventilation (Baseline, 30 minutes after budesonide administration)
Phase: PHASE4
Status: Recruiting
Start Date: 2026-04-27
Completion: 2028-04
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Collaborators: Australian Lung Health Initiative Pty Ltd
- Trishul Siddharthan, MD (PRINCIPAL_INVESTIGATOR) - University of Miami
- Drug: Albuterol Sulfate — Visit 1: Albuterol Sulfate (90mcg) two puffs will be administered via metered-dose inhaler (MDI) with spacer during the baseline study visit to obtain baseline imaging values.
- Drug: Albuterol-Budesonide — Visit 2: AIRSUPRA (Albuterol/Budesonide) (90mcg/80mcg) two puffs will be administered via MDI with spacer during this study visit. This intervention is used to evaluate its effect on ventilation defect percentage (VDP), ventilation heterogeneity (VH), and perfusion metrics derived from XV LVAS imaging